Shanghai Shenqi Pharmaceutical Investment Management Co Ltd
SSE:600613
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
|
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd
SSE:600613
|
3.3B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
948.8B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
563B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
282B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.9B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
288.1B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
225.6B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.6T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
146.4B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
98B EUR |
Loading...
|
Market Distribution
| Min | -416 945.9% |
| 30th Percentile | -1.5% |
| Median | 3.5% |
| 70th Percentile | 8.9% |
| Max | 17 382.1% |
Other Profitability Ratios
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd
Glance View
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. engages in the research and development, manufacture, and sale of antitumor, cardiovascular, cold and cough, children medicine, and anti fungi drugs. The company is headquartered in Shanghai, Shanghai and currently employs 1,371 full-time employees. is a China-based company principally engaged in research and development, manufacture and sale of pharmaceuticals. The Company’s products are targeted for the treatment of influenza, cardio cerebrovascular diseases, rheumatoid bone diseases and in the areas of oncology, antifungal, antipyretic and gynaecology. The firm's main products include cantharidin sodium vitamin B6 injection, cantharidin sodium injection and other Chinese patent drug products. The firm distributes its products in domestic market.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Shanghai Shenqi Pharmaceutical Investment Management Co Ltd is 3.3%, which is above its 3-year median of 2.7%.
Over the last 3 years, Shanghai Shenqi Pharmaceutical Investment Management Co Ltd’s Net Margin has increased from 3.1% to 3.3%. During this period, it reached a low of 2% on Dec 31, 2022 and a high of 3.5% on Jun 30, 2025.
